Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Gene Therapy for Relapsed and Refractory Multiple Myeloma by Guangzhou Bio-gene Technology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Gene Therapy for Relapsed and Refractory Multiple Myeloma is under clinical development by Guangzhou Bio-gene Technology and currently in Phase...
Gene Therapy for Relapsed and Refractory Multiple Myeloma by Guangzhou Bio-gene Technology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Gene Therapy for Relapsed and Refractory Multiple Myeloma is under clinical development by Guangzhou Bio-gene Technology and currently in Phase...
CD19 Universal CAR-Gamma Delta T by Guangzhou Bio-gene Technology for Systemic Lupus Erythematosus: Likelihood of Approval
CD19 Universal CAR-Gamma Delta T is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Systemic...
BCMA-GPRC5D CAR-T Cells by Guangzhou Bio-gene Technology for Relapsed Multiple Myeloma: Likelihood of Approval
BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Relapsed Multiple Myeloma....
BCMA-GPRC5D CAR-T Cells by Guangzhou Bio-gene Technology for Refractory Multiple Myeloma: Likelihood of Approval
BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Refractory Multiple Myeloma....